Search Results
Your search for ,jCo matches 1780 pages
Showing 801 - 850Patient-Reported Outcomes With Immediate Implant-Based or Autologous Breast Reconstruction
As reported in the Journal of Clinical Oncology by Pusic et al, patient-reported outcomes in the Mastectomy Reconstruction Outcomes Consortium Study indicate that autologous tissue breast reconstruction is associated with greater breast satisfaction and greater sexual and psychosocial well-being...
Cardiac Events After Radiotherapy for Locally Advanced Lung Cancer
An analysis of patients from 4 prospective radiotherapy trials for locally advanced non–small cell lung cancer (NSCLC) conducted at 2 centers in Michigan showed that grade ≥ 3 cardiac events occurred in more than 10% of patients. The study was reported by Dess et al in the Journal of...
Final Results of European Intergroup Trial of Early PET-Adapted Treatment in Hodgkin Lymphoma
Final results of the phase III EORTC/LYSA/FIL H10 trial confirm the benefits of early positron-emission tomography (PET)-adapted treatment in patients with stage I or II Hodgkin lymphoma. The results were reported by André et al in the Journal of Clinical Oncology. Study Details The...
Pembrolizumab in Platinum- and Cetuximab-Refractory Head and Neck Cancer
In the phase II KEYNOTE-055 trial, pembrolizumab (Keytruda) was found to produce durable responses in patients with platinum- and cetuximab (Erbitux)-refractory head and neck squamous cell carcinoma. Results of the trial were reported by Bauml et al in the Journal of Clinical Oncology....
Mercaptopurine Ingestion Habits and Risk of Relapse in Children With Acute Lymphoblastic Leukemia
In a report from the Children’s Oncology Group Study AALL03N1 published in the Journal of Clinical Oncology, Landier et al found no association between oral mercaptopurine ingestion habits in children with acute lymphoblastic leukemia and risk of relapse after adjustment for medication...
Anti–Trop-2 Antibody Drug Conjugate in Heavily Pretreated Metastatic Triple-Negative Breast Cancer
As reported in the Journal of Clinical Oncology by Bardia et al, the anti–Trop-2 antibody drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily pretreated metastatic triple-negative breast cancer. Trop-2, a glycoprotein initially identified ...
Intestinal Microbiota and Relapse After Allogeneic Hematopoietic Cell Transplantation
A retrospective study has shown that the presence and abundance of a particular bacterial group in the intestinal microbiota are associated with a significantly lower risk of relapse or disease progression after allogeneic hematopoietic cell transplantation. The findings were reported by Peled et...
Interleukin-15 Levels Associated With Lymphoma Response to CAR T-Cell Treatment
As reported by Kochenderfer et al in the Journal of Clinical Oncology, remission in patients with advanced lymphoma induced by treatment with chimeric antigen receptor (CAR) T cells targeting CD19 (CAR-19) is associated with elevated serum interleukin-15 (IL-15) levels. Study Details The study...
3-Year Follow-up of Japanese Trial of Alectinib in ALK-Positive NSCLC
Promising 3-year outcomes were found in patients from a Japanese phase I/II study of alectinib (Alecensa) in previously treated patients with ALK-positive non–small cell lung cancer (NSCLC). The findings were reported by Tamura et al in the Journal of Clinical Oncology. Study Details In the ...
Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Hypofractionated radiotherapy was noninferior to standard radiotherapy in biochemical-clinical failure disease-free survival in men with localized prostate cancer, according to a study reported by Catton et al in the Journal of Clinical Oncology. Study Details In the trial, 1,206 patients with...
Impact of 70-Gene Signature on Adjuvant Chemotherapy Decisions in Breast Cancer
In a Dutch observational study reported in the Journal of Clinical Oncology, Kuijer et al found that use of the MammaPrint 70-gene signature (70-GS) test changed physician-intended recommendations to administer adjuvant chemotherapy in half of patients with early-stage estrogen...
ASCO Launches Its New Journal Dedicated to Informatics
On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...
Celecoxib or Celecoxib/Zoledronic Acid in Men Initiating Hormone Therapy for Prostate Cancer
As reported by Mason et al in the Journal of Clinical Oncology, long-term survival results of the UK-based, multiarm, multistage platform–design STAMPEDE trial showed no survival benefit with the addition of celecoxib or celecoxib plus zoledronic acid in men initiating long-term hormone...
Multikinase Inhibitor Treatment Responses in Patients With RET-Rearranged NSCLC
In a report from the Global, Multicenter RET Registry in the Journal of Clinical Oncology, Gautschi et al documented response rates with multikinase RET inhibitors in patients with RET-rearranged non–small cell lung cancer (NSCLC). Study Details The study involved registry data (through...
Risk of Second Cancer in Hodgkin Lymphoma Survivors
In a study in the Swedish population reported in the Journal of Clinical Oncology, Sud et al found an increased risk of second cancers in survivors of Hodgkin lymphoma. Risk was further augmented in those with first-degree relatives with a cancer diagnosis. Study Details The study used data from...
Testosterone Replacement Therapy and Risk of Prostate Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Loeb et al found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among men developing the disease. Study Details The ...
Association of Metformin Use for Diabetes With Outcomes in HER2-Positive Breast Cancer
In an analysis from the phase III ALTTO trial reported in the Journal of Clinical Oncology, Sonnenblick et al found that among patients receiving adjuvant therapy for HER2-positive breast cancer, those with diabetes who received metformin had better outcomes than those who did not receive...
Factors Associated With Early Death in Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Green et al found that risk factors for death within 1 month of diagnosis of childhood cancer included age up to 1 year, specific diagnoses, and minority race/ethnicity. The study involved analysis of data from SEER (Surveillance,...
Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
As reported in the Journal of Clinical Oncology by Dhesy-Thind, ofJuravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer. The...
European Cohort Study of Vasectomy and Prostate Cancer Risk
In a large European cohort study reported in the Journal of Clinical Oncology, Smith Byrne et al found that vasectomy was not associated with an increased overall risk of prostate cancer or death from prostate cancer but appeared to increase the risk of lower-grade disease. Other studies have...
Evidence of Stage Shift in Ovarian Cancer Detected in UK Screening Study
As reported in the Journal of Clinical Oncology, Rosenthal et al found evidence of a shift to an earlier stage among ovarian cancers detected in high-risk women in the UK Familial Ovarian Cancer Screening Study. Study Details The study was performed to evaluate performance of screening using...
Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors
In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
Cisplatin-Based Chemotherapy in Pediatric Extracranial Malignant Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Shaikh et al, of the Children’s Oncology Group, found that event-free survival rates were not maintained with the use of reduced and compressed cisplatin-based regimens in children and adolescents with intermediate-risk extracranial...
Osimertinib in EGFR Inhibitor–Pretreated T790M-Positive Advanced NSCLC
In the phase II extension component of the phase I/II AURA trial, reported by Yang et al in the Journal of Clinical Oncology, osimertinib (Tagrisso) was found to be highly active in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor–pretreated T790M-positive advanced...
Risk of Adverse Health Outcomes in Testicular Cancer Survivors After Cisplatin-Based Chemotherapy
In a study reported in the Journal of Clinical Oncology, Fung et al found that although adverse health outcomes were common among testicular cancer survivors, there did not appear to be differences in such outcomes according to chemotherapy regimens commonly used to treat favorable-risk disease....
Late Relapse of Classical Hodgkin Lymphoma in German Hodgkin Study Group Trials
In an analysis of German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that the cumulative incidence of late relapse in patients with classical Hodgkin lymphoma was 6.9% at 20 years and that late relapse was more common among those with...
ASCO Endorses ACS Head and Neck Cancer Survivorship Care Guideline
As reported in the Journal of Clinical Oncology by Larissa Nekhlyudov, MD, MPH, of Brigham & Women’s Hospital, Harvard Medical School, and colleagues, ASCO has endorsed the 2016 American Cancer Society (ACS) guideline on head and neck cancer survivorship care. The endorsement was based on ...
Can Histone Deacetylase Inhibitors Reverse Resistance to Angiogenesis Inhibitors?
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al found evidence that the histone deacetylase (HDAC) inhibitor abexinostat may act to reverse resistance to the vascular endothelial growth factor (VEGF) inhibitor pazopanib (Votrient) via epigenetic modulation of VEGF in ...
Hormone Maintenance Therapy in Low-Grade Serous Cancer of the Ovary or Peritoneum
In a single-institution experience reported in the Journal of Clinical Oncology, Gershenson et al at MD Anderson Cancer Center found that hormonal maintenance therapy was associated with improved progression-free survival among women with stage II to IV low-grade serous carcinoma of the ovary or...
Clofarabine-Based Consolidation in Younger Patients With Acute Myeloid Leukemia in First Remission
In a French phase II trial reported in the Journal of Clinical Oncology, Thomas et al found that clofarabine-based consolidation may provide improved relapse-free survival vs conventional high-dose cytarabine in postremission treatment in younger patients with acute myeloid leukemia (AML) and no...
Effect of Adjuvant Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Trifiletti et al found that adjuvant chemoradiotherapy was associated with a survival benefit in patients with resected locally advanced head and neck cancer with negative surgical margins and no extracapsular ...
Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial
In a study reported in the Journal of Clinical Oncology, Borgquist et al found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone receptor–positive women in the BIG 1-98 trial. Study Details ...
Myeloablative vs Reduced-Intensity HCT for Acute Myeloid Leukemia and Myelodysplastic Syndromes
In a phase III trial reported in the Journal of Clinical Oncology, Scott et al found that myeloablative conditioning for allogeneic hematopoietic cell transplantation was associated with a reduced risk of relapse and a nonsignificant overall survival advantage vs reduced-intensity conditioning in...
ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers for Evaluation of Colorectal Cancer
As reported in the Journal of Clinical Oncology by Antonia Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...
Residual Cancer Burden, Breast Cancer Phenotype, and Long-Term Prognosis After Neoadjuvant Chemotherapy
In a study reported in the Journal of Clinical Oncology, Symmans et al found that residual cancer burden (RCB) after neoadjuvant chemotherapy was significantly prognostic for long-term outcome across breast cancer subtypes. Study Details The study included 5 patient cohorts from The University of ...
Italian Trial Adds Bevacizumab to Cisplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer
In an Italian phase III trial reported in the Journal of Clinical Oncology, Tiseo et al found that adding first-line bevacizumab (Avastin) to cisplatin/etoposide did not prolong overall survival in patients with extensive-disease small cell lung cancer. Study Details In the open-label trial, 204...
Patient Coaching and End-of-Life Discussions in Advanced Cancer
As reported by Rodenbach et al in the Journal of Clinical Oncology, a patient coaching session for patients with advanced cancer prior to an oncologist visit made it more likely that patients would discuss their prognosis during the visit. However, prognosis was still infrequently discussed. Study ...
Intentional Weight Loss in Postmenopausal Women May Be Linked to Reduced Endometrial Cancer Risk
Although many studies have linked obesity with an increased risk for endometrial cancer, information about the influence of weight loss on the cancer in postmenopausal women has been limited. Now, a study by Luo et al evaluating the association of weight change and endometrial cancer risk among...
Increased Risk of Cardiac Events With High Heart Dose in High-Dose Thoracic Radiotherapy
In a single-center pooled analysis reported in the Journal of Clinical Oncology, Wang et al found that a higher dose of radiation to the heart was associated with an increased risk of cardiac events in patients receiving high-dose radiation therapy for stage III non–small cell lung cancer...
ASCO Participates in Final White House Moonshot Event
On January 11, representatives from ASCO participated in the final event in the Cancer MoonshotSM “Making Health Care Better” series, which focused on community oncology, at the White House. ASCO community members attending the event, titled “Addressing the Cancer Challenge: Progress in Research,...
Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer
As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...
Intermittent Sunitinib Appears Feasible in Previously Untreated Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Ornstein et al found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. Study Details In the study, 37 patients with clear cell metastatic...
Immunotherapy 2.0 Named Advance of the Year in ASCO's Report
A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer...
ASCO Clinical Practice Guideline on Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses. The guideline was derived from an expert panel literature search for and...
How Does Sublingual Fentanyl Measure Up Against Subcutaneous Morphine in Managing Cancer Pain?
An Italian single-center trial compared treatment with sublingual fentanyl tablets and subcutaneous morphine in managing severe pain episodes in cancer patients receiving opioid treatment. In the Journal of Clinical Oncology, Zecca et al reported that the trial did not show noninferiority of...
Health-Related Quality of Life After Cancer Diagnosis in Adolescents/Young Adults
In a longitudinal study reported in the Journal of Clinical Oncology, Husson et al found that health-related quality of life improved between diagnosis and 2 years after diagnosis in adolescent/young adult (AYA) patients with cancer, but it remained impaired compared with population norms. Study...
Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy
In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...
Venetoclax Studied in Relapsed or Refractory Non-Hodgkin Lymphoma
The BCL-2 inhibitor venetoclax (Venclexta) was found to be active in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to a phase I study reported by Davids et al in the Journal of Clinical Oncology. Further study of this agent, including in combination therapy to augment...
Low Loss of Residual Lifetime for Patients With DLBCL in Remission Who Were Event-Free 24 Months After Treatment
In a Danish population–based study reported in the Journal of Clinical Oncology, Jakobsen et al found that patients with diffuse large B-cell lymphoma (DLBCL) in first remission and event-free at 24 months after treatment have a low loss of residual lifetime compared with the general...
